Bi-allelic JAM2 Variants Lead to Early-Onset Recessive Primary Familial Brain Calcification.

Fahr disease JAM2 JAM3 MYORG OCLN SLC20A2 familial idiopathic basal ganglia calcification knock out mouse model primary familial brain calcification recessive brain calcification

Journal

American journal of human genetics
ISSN: 1537-6605
Titre abrégé: Am J Hum Genet
Pays: United States
ID NLM: 0370475

Informations de publication

Date de publication:
05 03 2020
Historique:
received: 09 10 2019
accepted: 10 02 2020
entrez: 7 3 2020
pubmed: 7 3 2020
medline: 6 5 2020
Statut: ppublish

Résumé

Primary familial brain calcification (PFBC) is a rare neurodegenerative disorder characterized by a combination of neurological, psychiatric, and cognitive decline associated with calcium deposition on brain imaging. To date, mutations in five genes have been linked to PFBC. However, more than 50% of individuals affected by PFBC have no molecular diagnosis. We report four unrelated families presenting with initial learning difficulties and seizures and later psychiatric symptoms, cerebellar ataxia, extrapyramidal signs, and extensive calcifications on brain imaging. Through a combination of homozygosity mapping and exome sequencing, we mapped this phenotype to chromosome 21q21.3 and identified bi-allelic variants in JAM2. JAM2 encodes for the junctional-adhesion-molecule-2, a key tight-junction protein in blood-brain-barrier permeability. We show that JAM2 variants lead to reduction of JAM2 mRNA expression and absence of JAM2 protein in patient's fibroblasts, consistent with a loss-of-function mechanism. We show that the human phenotype is replicated in the jam2 complete knockout mouse (jam2 KO). Furthermore, neuropathology of jam2 KO mouse showed prominent vacuolation in the cerebral cortex, thalamus, and cerebellum and particularly widespread vacuolation in the midbrain with reactive astrogliosis and neuronal density reduction. The regions of the human brain affected on neuroimaging are similar to the affected brain areas in the myorg PFBC null mouse. Along with JAM3 and OCLN, JAM2 is the third tight-junction gene in which bi-allelic variants are associated with brain calcification, suggesting that defective cell-to-cell adhesion and dysfunction of the movement of solutes through the paracellular spaces in the neurovascular unit is a key mechanism in CNS calcification.

Identifiants

pubmed: 32142645
pii: S0002-9297(20)30049-5
doi: 10.1016/j.ajhg.2020.02.007
pmc: PMC7058839
pii:
doi:

Substances chimiques

Cell Adhesion Molecules 0
JAM2 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

412-421

Subventions

Organisme : Wellcome Trust
ID : WT093205MA
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S005021/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S01165X/1
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT104033AIA
Pays : United Kingdom

Investigateurs

Stanislav Groppa (S)
Blagovesta Marinova Karashova (BM)
Wolfgang Nachbauer (W)
Sylvia Boesch (S)
Larissa Arning (L)
Dagmar Timmann (D)
Bru Cormand (B)
Belen Pérez-Dueñas (B)
Gabriella Di Rosa (G)
Jatinder S Goraya (JS)
Tipu Sultan (T)
Jun Mine (J)
Daniela Avdjieva (D)
Hadil Kathom (H)
Radka Tincheva (R)
Selina Banu (S)
Mercedes Pineda-Marfa (M)
Pierangelo Veggiotti (P)
Michel D Ferrari (MD)
Alberto Verrotti (A)
Giangluigi Marseglia (G)
Salvatore Savasta (S)
Mayte García-Silva (M)
Alfons Macaya Ruiz (AM)
Barbara Garavaglia (B)
Eugenia Borgione (E)
Simona Portaro (S)
Benigno Monteagudo Sanchez (BM)
Richard Boles (R)
Savvas Papacostas (S)
Michail Vikelis (M)
Eleni Zamba Papanicolaou (EZ)
Efthymios Dardiotis (E)
Shazia Maqbool (S)
Shahnaz Ibrahim (S)
Salman Kirmani (S)
Nuzhat Noureen Rana (NN)
Osama Atawneh (O)
George Koutsis (G)
Marianthi Breza (M)
Salvatore Mangano (S)
Carmela Scuderi (C)
Eugenia Borgione (E)
Giovanna Morello (G)
Tanya Stojkovic (T)
Massimi Zollo (M)
Gali Heimer (G)
Yves A Dauvilliers (YA)
Pasquale Striano (P)
Issam Al-Khawaja (I)
Fuad Al-Mutairi (F)
Hamed Sherifa (H)

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Références

Nat Genet. 2013 Sep;45(9):1077-82
pubmed: 23913003
Parkinsonism Relat Disord. 2017 Apr;37:1-10
pubmed: 28162874
Brain Behav Immun. 2018 Oct;73:3-20
pubmed: 29920328
Am J Hum Genet. 2010 Dec 10;87(6):882-9
pubmed: 21109224
Acta Neuropathol. 1987;73(1):62-6
pubmed: 3604574
Neurol Sci. 2015 May;36(5):787-94
pubmed: 25686613
Am J Pathol. 2018 Aug;188(8):1865-1881
pubmed: 29803831
Nat Genet. 2015 Jun;47(6):579-81
pubmed: 25938945
Acta Neuropathol. 2005 Jun;109(6):643-53
pubmed: 15937691
Blood. 2001 Dec 15;98(13):3699-707
pubmed: 11739175
Dev Med Child Neurol. 2014 Jul;56(7):612-26
pubmed: 24372060
Neuron. 2018 Jun 27;98(6):1116-1123.e5
pubmed: 29910000
Am J Hum Genet. 2010 Sep 10;87(3):354-64
pubmed: 20727516
Neuron. 2016 Aug 17;91(4):824-836
pubmed: 27499083
Neuropathology. 2016 Aug;36(4):365-71
pubmed: 26635128
Brain. 2019 Jun 1;142(6):1573-1586
pubmed: 31009047
Brain. 2020 Feb 1;143(2):491-502
pubmed: 31851307

Auteurs

Lucia V Schottlaender (LV)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, WC1N3BG London, UK; Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, WC1N 1EH London, UK; Argentine National Scientific and Technological Research Council (CONICET), C1425FQB Buenos Aires, Argentina; FLENI Neurological Research Institute, C1428 AQK Buenos Aires, Argentina.

Rosella Abeti (R)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, WC1N3BG London, UK.

Zane Jaunmuktane (Z)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, WC1N3BG London, UK; Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, Queen Square, London WC1N 3BG, UK.

Carol Macmillan (C)

Department of Pediatrics, University of Chicago, Chicago, IL 60637, USA.

Viorica Chelban (V)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, WC1N3BG London, UK.

Benjamin O'Callaghan (B)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, WC1N3BG London, UK.

John McKinley (J)

Department of Neurology, Dublin Neurological Institute at the Mater Misericordiae University Hospital, 57 Eccles St, Dublin 7 DO7W7XF, Ireland; Regional Neurosciences Centre, Royal Victoria Hospital, Belfast BT12 6BA, UK.

Reza Maroofian (R)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, WC1N3BG London, UK.

Stephanie Efthymiou (S)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, WC1N3BG London, UK.

Alkyoni Athanasiou-Fragkouli (A)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, WC1N3BG London, UK.

Raeburn Forbes (R)

Neurology Centre, Southern HSC Trust, Craigavon Area Hospital, Portadown BT63 5QQ, UK.

Marc P M Soutar (MPM)

Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, UK.

John H Livingston (JH)

Paediatric Neurology, The Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Leeds LS1 3EX, UK.

Bernardett Kalmar (B)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, WC1N3BG London, UK.

Orlando Swayne (O)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, WC1N3BG London, UK; The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK.

Gary Hotton (G)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, WC1N3BG London, UK; The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK.
Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, WC1N3BG London, UK.

Alan Pittman (A)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, WC1N3BG London, UK.

João Ricardo Mendes de Oliveira (JR)

Universidade Federal de Pernambuco, Departamento de Neuropsiquiatria, Recife 50670-901, Brazil.

Maria de Grandis (M)

Aix-Marseille University, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, 13009 Marseille, France.

Angela Richard-Loendt (A)

Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, UK.

Francesca Launchbury (F)

Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, UK.

Juri Althonayan (J)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, WC1N3BG London, UK.

Gavin McDonnell (G)

Regional Neurosciences Centre, Royal Victoria Hospital, Belfast BT12 6BA, UK.

Aisling Carr (A)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, WC1N3BG London, UK; The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK.

Suliman Khan (S)

CENTOGENE AG, Rostock 18055, Germany.

Christian Beetz (C)

CENTOGENE AG, Rostock 18055, Germany.

Atil Bisgin (A)

Medical Genetics Department of Medical Faculty & AGENTEM (Adana Genetic Diseases Diagnosis and Treatment Center), Çukurova University, Adana 01330, Turkey.

Sevcan Tug Bozdogan (S)

Medical Genetics Department of Medical Faculty & AGENTEM (Adana Genetic Diseases Diagnosis and Treatment Center), Çukurova University, Adana 01330, Turkey.

Amber Begtrup (A)

GeneDx, 207 Perry Parkway, Gaithersburg, MD 20877, USA.

Erin Torti (E)

GeneDx, 207 Perry Parkway, Gaithersburg, MD 20877, USA.

Linda Greensmith (L)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, WC1N3BG London, UK.

Paola Giunti (P)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, WC1N3BG London, UK.

Patrick J Morrison (PJ)

Centre for Cancer Research and Cell Biology, Queens University, Belfast BT9 7AE, UK.

Sebastian Brandner (S)

Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, Queen Square, London WC1N 3BG, UK.

Michel Aurrand-Lions (M)

Aix-Marseille University, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, 13009 Marseille, France.

Henry Houlden (H)

Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, WC1N3BG London, UK; The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK; Neurogenetics Laboratory and Clinical Service, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK. Electronic address: h.houlden@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH